• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Are Excessive Serum Bile Acids Associated with Low Birth Weight and Intrauterine Growth Restriction?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Increased serum total bile acid (sTBA) levels during pregnancy are associated with adverse perinatal outcomes
    • Connection between sTBA concentration, intrahepatic cholestasis of pregnancy (ICP) and intrauterine growth restriction (IUGR) remains unclear
  • Song et al. (JAMA Network Open, 2021) examined the association between maternal sTBA concentration during pregnancy and risk for IUGR

METHODS:

  • Retrospective cohort study
  • Participants
    • Live singleton neonates
    • Antenatal examination records available
  • Exposures
    • Maternal sTBA concentration during pregnancy
  • Study design
    • Regression modeling used to determine relationship between maternal sTBA and fetal birth weight
    • Adjustments for counfounders: Gestational age | Maternal age | Prepregnancy BMI | Race | Parity | Education level | Fetal sex
    • Gestational hypercholanemia definition: sTBA ≥4.08 μg/mL
  • Primary outcomes
    • Fetal birth weight
      • Macrosomia: Fetal birth weight ≥4000 g
      • LBW: Fetal birth weight <2500 g
    • IUGR: Ultrasound estimation based on EFW or AC <10% of birth population (adjusted for fetal sex, gestational age, potential causative pathologic conditions)

RESULTS:

  • 68,245 singleton pregnancies
    • Mean (SD) age: 30.5 (3.8) years
    • 98.4% were Han Chinese
    • 73.5% were nulliparous
  • There was an inverted J-shaped association between maternal sTBA level during pregnancy and fetal birth weight
    • Steep decrease in birth weight at high sTBA levels
      • Estimated mean birth weight for sTBA of 40.8 ug/mL: 2879 g
    • Greater birth weights at lower sTBA levels
      • Estimated mean birth weight for sTBA 0.4 μg/mL: 3290 g
      • Estimated mean birth weight for sTBA 4.1 μg/mL: 3334 g
  • Gestational hypercholanemia was associated with lower birth weight and higher incidence of IUGR
    • Birth weight (P=0.005)
      • With gestational hypercholanemia: Estimated adjusted mean birth weight 3309 g
      • Without: 3338 g
    • Incidence of IUGR (P<0.001)
      • With gestational hypercholanemia: 1.4%
      • Without: 0.5%
  • Gestational hypercholanemia was associated with an increased risk for
    • LBW: Adjusted odds ratio (aOR) 1.29 (95% CI, 1.09 to 1.53)
    • IUGR: aOR 2.18 (95% CI, 1.62 to 2.91)
  • The highest risk for LBW and IUGR occurred among pregnant individuals with both hypertensive disorders of pregnancy and hypercholanemia
    • LBW: aOR 9.13 (95% CI, 6.88 to 12.12)
    • IUGR: aOR 19.14 (95% CI, 12.09 to 30.28)

CONCLUSION:

  • Gestational hypercholanemia (sTBA ≥4.08 μg/mL) was associated with an increased risk for LBW and IUGR
  • Of note, hypertensive disorders of pregnancy and hypercholanemia resulted in highest (additive) risks for LBW and IUGR
  • The authors state

…it is suggested that more attention should be paid to the recognition and management of gestational hypercholanemia, especially in pregnant individuals with HDP

Additional studies, including prospective cohort studies and randomized clinical trials, are needed to confirm the current findings and potential benefits of lowering sTBA concentrations using drugs (such as ursodesoxycholic acid) in these patients

Learn More – Primary Sources:

Association of Elevated Maternal Serum Total Bile Acids With Low Birth Weight and Intrauterine Fetal Growth Restriction

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Risk of Stillbirth with Intrahepatic Cholestasis of Pregnancy: What do Bile Acid Concentrations Tell Us?
More from the PITCHES Trial: Subgroup Analysis of Participants with Intrahepatic Cholestasis of Pregnancy and UDCA Treatment

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site